New Phase 3 Trial for VANFLYTA® in Acute Myeloid Leukemia
In an impressive advancement in the fight against acute myeloid leukemia (AML), Daiichi Sankyo has initiated the QuANTUM-Wild phase 3 trial to evaluate the efficacy of VANFLYTA® (quizartinib) combined with standard chemotherapy treatment. This trial specifically targets adults who have been newly diagnosed with FLT3-ITD negative AML and seeks to offer a new lifeline for these patients.
Understanding the Importance of AML Treatment
AML is a particularly aggressive form of blood cancer, with a disheartening overall five-year survival rate of about 32%. Current therapies using FLT3 inhibitors have been beneficial for patients with specific FLT3 mutations, but there is a significant gap for the roughly 90% of AML patients who overexpress FLT3 without these mutations. This trial's focus on FLT3-ITD negative patients is crucial, as there are currently no approved FLT3 inhibitors for this demographic.
The Rationale Behind the Trial
Initial data have indicated that VANFLYTA may improve outcomes for AML patients lacking FLT3 mutations. Mark Rutstein, M.D., Global Head of Oncology Clinical Development at Daiichi Sankyo, emphasized the potential impact of this combination therapy. With the QuANTUM-Wild trial, there is hope that VANFLYTA can reduce relapse rates and enhance overall survival for AML patients in desperate need of effective treatments.
Details of the QuANTUM-Wild Trial
The QuANTUM-Wild trial is designed as a randomized, double-blind, placebo-controlled study that involves adult participants aged 18 to 70. Patients will be allocated into three treatment arms, receiving either VANFLYTA or a placebo in conjunction with established chemotherapy protocols. The trial has a significant objective—it's anticipated that around 700 patients will be enrolled across various regions, including Asia, Australia, Europe, and the Americas.
Endpoints and Treatment Arms
The primary endpoint of this trial is overall survival, a critical measure for assessing the efficacy of new cancer treatments. Secondary endpoints will include event-free survival, duration of complete response, and safety assessments. The structured approach aims to gather comprehensive data that could potentially reshape AML treatment protocols.
The Need for Innovative Treatments in AML
Approximately 144,000 new cases of AML were documented globally within a recent year, indicating an urgent need for expanded treatment options. The introduction of VANFLYTA is hoped to bring the first targeted therapy specifically for patients without FLT3 mutations, marking a significant milestone in AML treatment.
Background on VANFLYTA®
Daiichi Sankyo’s VANFLYTA is recognized as a highly selective FLT3 inhibitor, previously approved in over 30 countries. The drug has primarily been administered to patients diagnosed with FLT3-ITD positive AML. The initiation of the QuANTUM-Wild trial for FLT3-ITD negative AML is a pivotal move and symbolizes the company's commitment to addressing unmet medical needs.
About Daiichi Sankyo
Daiichi Sankyo is a global healthcare leader, rooted in over 120 years of innovative practices. This organization is dedicated to developing and delivering quality medicines that enhance the lives of patients battling severe diseases. Their focus on oncology, cardiology, and complex conditions showcases the breadth of their commitment to healthcare innovation.
Frequently Asked Questions
What is the purpose of the QuANTUM-Wild trial?
The QuANTUM-Wild trial aims to evaluate the effectiveness of VANFLYTA in adult patients with newly diagnosed FLT3-ITD negative AML in combination with standard chemotherapy.
How many patients will participate in the trial?
Approximately 700 patients from various continents are expected to enroll in the QuANTUM-Wild trial.
What are the primary endpoints of the trial?
The primary endpoint is overall survival, while secondary endpoints include event-free survival and duration of complete response among others.
Why is there a focus on FLT3-ITD negative AML patients?
There are currently no approved FLT3 inhibitors for patients without FLT3 mutations, and this trial aims to address that urgent need in the treatment landscape.
When is the trial expected to begin?
The trial has already been initiated, marking the starting point for evaluation and data collection.
